Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2020; 11(7):1727-1736. doi:10.7150/jca.40982 This issue Cite

Research Paper

FKBP4 is a malignant indicator in luminal A subtype of breast cancer

Hanchu Xiong1,2*, Zihan Chen3*, Wenwen Zheng2, Jing Sun2, Qingshuang Fu4, Rongyue Teng1, Jida Chen1, Shuduo Xie1, Linbo Wang1, Xiao-Fang Yu2✉, Jichun Zhou1✉

1. Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China.
2. Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
3. Surgical Intensive Care Unit, First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, 310016, China.
4. Rui An Hospital of Traditional Chinese Medicine, Wenzhou, 325200, China.
* These authors contributed equally

✉ Corresponding authors: Xiao-Fang Yu, E-mail: xfyu1edu.cn; Jichun Zhou, E-mail: jichun-zhouedu.cn

Citation:
Xiong H, Chen Z, Zheng W, Sun J, Fu Q, Teng R, Chen J, Xie S, Wang L, Yu XF, Zhou J. FKBP4 is a malignant indicator in luminal A subtype of breast cancer. J Cancer 2020; 11(7):1727-1736. doi:10.7150/jca.40982. https://www.jcancer.org/v11p1727.htm
Other styles

File import instruction

Abstract

Purpose: FKBP4 is a member of the immunophilin protein family, which plays a role in immunoregulation and basic cellular processes involving protein folding and trafficking associated with HSP90. However, the relationship between abnormal expression of FKBP4 and clinical outcome in luminal A subtype breast cancer (LABC) patients remains to be elucidated.

Methods: Oncomine, bc-GenExMiner and HPA database were used for data mining and analyzing FKBP4 and its co-expressed genes. GEPIA database was used for screening co-expressed genes of FKBP4.

Results: For the first time, we found that higher FKBP4 expression correlated with LABC patients and worse survival. Moreover, the upregulated co-expressed genes of FKBP4 were assessed to be significantly correlated with worse survival in LABC, and might be involved in the biological role of FKBP4.

Conclusion: The expression status of FKBP4 is a significant prognostic indicator and a potential drug target for LABC.

Keywords: FKBP4, luminal A subtype breast cancer, co-expressed genes, bioinformatics analysis

Citation styles

APA
Xiong, H., Chen, Z., Zheng, W., Sun, J., Fu, Q., Teng, R., Chen, J., Xie, S., Wang, L., Yu, X.F., Zhou, J. (2020). FKBP4 is a malignant indicator in luminal A subtype of breast cancer. Journal of Cancer, 11(7), 1727-1736. https://doi.org/10.7150/jca.40982.

ACS
Xiong, H.; Chen, Z.; Zheng, W.; Sun, J.; Fu, Q.; Teng, R.; Chen, J.; Xie, S.; Wang, L.; Yu, X.F.; Zhou, J. FKBP4 is a malignant indicator in luminal A subtype of breast cancer. J. Cancer 2020, 11 (7), 1727-1736. DOI: 10.7150/jca.40982.

NLM
Xiong H, Chen Z, Zheng W, Sun J, Fu Q, Teng R, Chen J, Xie S, Wang L, Yu XF, Zhou J. FKBP4 is a malignant indicator in luminal A subtype of breast cancer. J Cancer 2020; 11(7):1727-1736. doi:10.7150/jca.40982. https://www.jcancer.org/v11p1727.htm

CSE
Xiong H, Chen Z, Zheng W, Sun J, Fu Q, Teng R, Chen J, Xie S, Wang L, Yu XF, Zhou J. 2020. FKBP4 is a malignant indicator in luminal A subtype of breast cancer. J Cancer. 11(7):1727-1736.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use